Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

GLAXOSMITHKLINE

(GSK)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
08/19/2019 08/20/2019 08/21/2019 08/22/2019 08/23/2019 Date
1664.6(c) 1666.4(c) 1685(c) 1676(c) 1691.2(c) Last
5 409 924 7 274 085 4 171 547 7 962 109 5 547 532 Volume
+0.40% +0.11% +1.12% -0.53% +0.91% Change
More quotes
Financials (GBP)
Sales 2019 32 481 M
EBIT 2019 8 745 M
Net income 2019 4 773 M
Debt 2019 22 986 M
Yield 2019 4,73%
Sales 2020 34 621 M
EBIT 2020 9 438 M
Net income 2020 4 860 M
Debt 2020 22 166 M
Yield 2020 4,73%
P/E ratio 2019 17,7x
P/E ratio 2020 17,3x
EV / Sales2019 3,28x
EV / Sales2020 3,06x
Capitalization 83 688 M
More Financials
Company
GlaxoSmithkline is the world's No. 2 pharmaceutical group. Net sales break down by family of products as follows: - pharmaceutical products (56%): intended for respiratory diseases (40.1% of net sales), HIV infection (27.3%), immune system disorders (2.7%) ) and other (29,8%); - OTC and... 
Sector
Pharmaceuticals
Calendar
09/26 | 03:30amInvestor Meeting
More about the company
Surperformance© ratings of GlaxoSmithKline
Trading Rating : Investor Rating :
More Ratings
Latest news on GLAXOSMITHKLINE
08/23GSK builds oncology pipeline as drug shown to help myeloma patients
RE
08/23GLAXOSMITHKLINE : GSK - positive results from pivotal DREAMM-2 study
PU
08/23GLAXOSMITHKLINE : Achieves Positive Results Blood Cancer Treatment Study
DJ
08/22GSK submits first regulatory application for daprodustat in Japan for patient..
AQ
08/22GSK's long acting HIV injection gets boost from study
RE
08/22GLAXOSMITHKLINE : ViiV Healthcare Reports Positive HIV Trial Results
DJ
08/22GLAXOSMITHKLINE : ViiV results positive for every 2 month injection
PU
08/21LONDON STOCK EXCHANGE : Oil majors, exporters boost FTSE 100; Fed minutes eyed
RE
08/21GSK SUBMITS REGULATORY FILE IN JAPAN : Daprodustat
PU
08/20Board of directors meeting of GlaxoSmithKline Consumer Healthcare Pakistan Li..
AQ
More news
Analyst Recommendations on GLAXOSMITHKLINE
More recommendations
Sector news : Pharmaceuticals - NEC
08/23ALLERGAN : Form 8.3 -
DJ
08/23NOVARTIS : Delay on Data Manipulation Probed
DJ
08/22Alexion Up Nearly 8%, on Pace for Largest Percent Increase Since April 2018 -..
DJ
08/22ABBVIE : Form 8.3 -
DJ
08/22ALLERGAN : Form 8.3 -
DJ
More sector news : Pharmaceuticals - NEC
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 22
Average target price 1 704,90  GBp
Last Close Price 1 691,20  GBp
Spread / Highest target 17,4%
Spread / Average Target 0,81%
Spread / Lowest Target -17,2%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Paul Dingemans Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Technology & Digital Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE13.41%102 699
JOHNSON & JOHNSON-1.02%337 101
ROCHE HOLDING LTD.11.71%237 836
MERCK AND COMPANY11.16%217 478
NOVARTIS18.13%204 739
PFIZER-19.63%189 936